Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. develops clinical-stage oncology therapies designed to counter mechanisms of therapeutic resistance in cancer. News about ORIC commonly covers rinzimetostat (ORIC-944), a selective allosteric PRC2/EED inhibitor studied in prostate cancer and metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations.
Recurring updates include clinical and preclinical data presentations, development-dose decisions, oncology conference presentations, quarterly financial results, cash runway disclosures, at-the-market equity financing, and Nasdaq Rule 5635(c)(4) inducement equity grants.
ORIC Pharmaceuticals reported a strong financial position, with cash and investments totaling $305.9 million, sufficient to support operations into 2024. The company achieved significant milestones, including the clearance of the IND for ORIC-533 and the presentation of initial data for ORIC-101 at ASCO. The Phase 1 trial of ORIC-101 in prostate cancer is on track for a data readout in 2H21, and the first patient for ORIC-533 is anticipated to be dosed in the same timeframe.
ORIC Pharmaceuticals has received FDA clearance for its Investigational New Drug Application (IND) for ORIC-533, marking the initiation of its first-in-human clinical trial. This small molecule inhibitor targets CD73, aiming to combat resistance in cancer therapies. The company plans to begin a Phase 1 trial in the second half of 2021, focusing on safety and preliminary efficacy. This IND filing is part of a broader strategy, with two additional filings expected later this year. ORIC-533 shows promising preclinical results, indicating potential best-in-class capabilities.
ORIC Pharmaceuticals announced initial safety data from its Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel. The treatment was well tolerated, with mostly Grade 1 or 2 adverse events and no treatment-related discontinuations. Key findings include strong plasma concentrations and no drug-drug interaction. Notably, the treatment showed antitumor activity in heavily pretreated patients, especially those with late-line relapsed pancreatic cancer experiencing extended progression-free survival. Updated trial data is expected in 2022.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced that CEO Jacob Chacko, M.D., will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 1:30 p.m. ET. A live webcast will be accessible through the investor section of ORIC's website, with a replay available for 90 days post-event. ORIC is focused on developing cancer treatments that tackle therapeutic resistance. Their lead candidate, ORIC-101, is currently in Phase 1b trials, targeting advanced solid tumors and metastatic prostate cancer.
ORIC Pharmaceuticals has announced a conference call and webcast on June 2, 2021, at 5:00 p.m. ET to review initial data from the ongoing Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist combined with nab-paclitaxel for advanced solid tumors. The data will also be presented at the ASCO Annual Meeting from June 4-8, 2021. ORIC-101 is part of two Phase 1b trials addressing therapeutic resistance in cancer. The call will feature insights from Professor Pamela Munster, a key investigator.
ORIC Pharmaceuticals reported its financial results for Q1 2021, highlighting progress in its oncology pipeline. The lead program, ORIC-101, is on track for Phase 1b data readouts in 2021, with two abstracts accepted for presentation at the ASCO Annual Meeting. The company anticipates filing INDs for ORIC-533, ORIC-944, and ORIC-114 within the year. Financially, cash and equivalents totaled $278.1 million, expected to fund operations through mid-2023. R&D expenses rose to $11.7 million, primarily due to advancements in product candidates, while G&A expenses increased to $4.9 million.
ORIC Pharmaceuticals announced that two abstracts featuring preliminary results from the Phase 1b study of ORIC-101 in combination with nab-paclitaxel are set for presentation at the 2021 ASCO Annual Meeting from June 4 - 8, 2021. The initial data will highlight the effects of ORIC-101, a glucocorticoid receptor antagonist, on patients with advanced solid tumors. The company plans to release data from a second trial involving enzalutamide later this year. These presentations aim to support ORIC's efforts in addressing therapeutic resistance in cancer treatments.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) showcased four preclinical studies at the 2021 AACR virtual annual meeting, focusing on its innovative oncology treatments. Key highlights include ORIC-101's ability to overcome resistance in prostate cancer, ORIC-533's potential to reverse tumor immunosuppression, ORIC-944's superior efficacy in prostate cancer models, and ORIC-114's promising results in targeting EGFR and HER2 mutations.
These findings suggest significant progress in developing therapies that may enhance treatment effectiveness against resistant cancer types.
ORIC Pharmaceuticals reported significant advancements in its clinical operations for the year ended December 31, 2020. Their leading program, ORIC-101, is undergoing Phase 1b trials with anticipated interim data readouts slated for 2021. The company aims to file three IND/CTA applications for ORIC-533, ORIC-944, and ORIC-114, enhancing their development pipeline. As of December 31, 2020, cash and investments totaled $293.6 million, projected to sustain operations into the second half of 2023. However, R&D expenses rose significantly, indicating increased investment in pipeline development.
ORIC Pharmaceuticals, a clinical stage oncology company, announced four preclinical poster presentations at the 2021 AACR virtual annual meeting scheduled for April 10-15, 2021. The data focuses on ORIC's lead program ORIC-101 and three other candidates: ORIC-533, ORIC-944, and ORIC-114, which aim to address cancer resistance mechanisms. Each candidate shows potential best-in-class differentiation, with ORIC-101 reversing GR-mediated resistance in prostate cancer models. These advancements underscore ORIC's commitment to improving cancer treatment outcomes.